Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
The new year began with a fairly low level of clinical trial news. Here’s a look.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.
PRESS RELEASES